These findings suggest targeting clock-regulated crosstalk between TME and cancer cells will help to develop a novel prognosis signature and effective clock-oriented immunotherapies that may have synergistic effects with conventional therapies to increase the effectiveness of glioma treatment. This evidence concerns the gene CLOCK and cancer.